Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 5, 2010, Pages 452-458

  Maraveyas, Anthony ^a   Ettelaie, Camille ^b   Echrish, Hussein ^a   Li, Chao ^b   Gardiner, Eric ^c   Greenman, John ^a   Madden, Leigh A ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c Freelance Statistical Consultant ^*  (United Kingdom)

Author keywords

Blood borne tissue factor; dalteparin; low molecular weight heparin; pancreatic cancer

Indexed keywords

DALTEPARIN; GEMCITABINE; LOW MOLECULAR WEIGHT HEPARIN; MARKER; THROMBOPLASTIN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CELL INVASION; CELL MIGRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PANCREAS CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT RESPONSE; VASCULAR THROMBOEMBOLISM;

AGED; DALTEPARIN; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; THROMBOPLASTIN; VENOUS THROMBOEMBOLISM;

EID: 77954656515     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328338dc49     Document Type: Article

References (28)

1. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004; 5:655-663.
2. Sgouros J, Maraveyas A. Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncol 2008; 47:337-346.
3. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003; 124:58S-68S.
4. Bromberg ME, Sundaram R, Homer RJ, Garen A, Konigsberg WH. Role of tissue factor in metastasis: functions of the cytoplasmatic and extracellular domains of the molecule. Thromb Haem 1999; 82:88-92.
5. Koomagi R, Volm M. Tissue-factor expression in human nonsmall-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998; 79:19-22.
6. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000; 83:164-170.
7. Ueda C, Hirohata Y, Kihara Y, Nakamura H, Abe S, Akahane K, et al. Pancreatic cancer complicated by disseminated intravascular coagulation associated with production of tissue factor. J Gastroenterol 2001; 36:848-850.
8. Förster Y, Meye A, Albrecht S, Kotzsch M, Füssel S, Wirth MP, Schwenzer B. Tissue specific expression and serum levels of human tissue factor in patients with urological cancer. Cancer Lett 2003; 193:65-73.
9. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105:1734-1741.
10. Gerlach R, Scheuer T, Bohm M, Beck J, Woszczyk A, Raabe A, et al. Increased levels of plasma tissue factor pathway inhibitor in patients with glioblastoma and intracerebral metastases. Neurol Res 2003; 25:335-338.
11. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A 1995; 92:8205-8209.
12. Kakkar AK, Chinswangwatanakul V, Lemoine NR, Tebbutt S, Williamson RC. Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma. Br J Surg 1999; 86:890-894.
13. Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82:1101-1104.
14. Khorana AA, Ahrendt SA, Ryan CK, Taubman MB, Hu YC, Ahrendt SA. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13:2870-2875.
15. Han LY, Landen CN Jr, Kamat AA, Bender DP, Mueller P, Schmandt R, et al. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 2006; 24:755-761.
16. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999; 91:22-36.
17. Smorenburg SM, Van Noorden CJF. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001; 53:93-105.
18. Fareed J, Hoppensteadt D, Cort S, Iqbal O, Bacher P, Fareed D, et al. Enoxaparin (E) and warfarin (W) differentially regulate tissue factor (TF), tissue factor pathway inhibitor (TFPI) and thrombin activatable fibrinolytic inhibitor (TAFI) in cancer patients with thrombosis. J Clin Oncol 2005; 23:2057.
19. Maraveyas A, Holmes M, Lofts F, Garadi KK, Gardiner E, Sgouros J. Chemoanticoagulation versus chemotherapy in advanced pancreatic cancer (APC): results of the interim analysis of the FRAGEM trial. J Clin Oncol 2007; 25:4583.
20. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Madiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-2413.
21. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Lowmolecular- weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349:146-153.
22. Maraveyas A, Li C, Greenman J, Ettelaie C. Serum tissue factor levels in pancreatic cancer patients treated with therapeutic dose dalteparin and gemcitabine, in a randomised phase IIb trial FRAGEM. 'Genes & Cancer 2004'; Warwick, UK.
23. Ettelaie C, Li C, Collier MEW, Pradier A, Frentzou GA, Wood CG, et al. Differential functions of tissue factor in the trans-activation of cellular signalling pathways. Atherosclerosis 2007; 194:88-101.
24. Pradier A, Ettelaie C. The influence of exogenous tissue factor on the regulators of proliferation and apoptosis in endothelial cells. J Vasc Res 2007; 45:19-32.
25. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Sumiyoshi A. Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haem 1996; 75:389-392.
26. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349:769-771.
27. Marmur JD, Thiruvikraman SV, Fyfe BS, Guhu A, Sharma SK, Ambrose JA, et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94:1226-1232.
28. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS. Tissue factor/factorVIIa inhibitors block angiogenesis and tumour growth through nonhemostatic mechanism. Cancer Res 2003; 63:2997-3000.